Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 15 Jun
    2017

    First patient dosed in food matrix compatibility study intended to form part of US Phase III registration package for lead product, Infacort®

    Successful dosing in healthy volunteers. 

    Read More

  • 18 May
    2017

    Diurnal announces grant of first US patent for lead product, Infacort®

    Composition of matter patent in this key territory provides protection to 2034

    Read More

  • 20 Mar
    2017

    Interim Results for the six months ended 31 December 2016

    On track to becoming a world leading specialty pharma company in endocrinology

    Read More